Galapagos Launches Global ISABELA Program Testing GLPG1690 in IPF Patients
Galapagos has started the worldwide ISABELA Phase 3 program to evaluate the potential of GLPG1690 as a treatment for idiopathic pulmonary fibrosis (IPF), reporting that the first participant has already been treated. GLPG1690 inhibits autotaxin, an enzyme that is thought to be involved in tissue scarring (fibrosis) and…